Cargando…
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition...
Autores principales: | Lorente, David, Omlin, Aurelius, Zafeiriou, Zafeiris, Nava-Rodrigues, Daniel, Pérez-López, Raquel, Pezaro, Carmel, Mehra, Niven, Sheridan, Elizabeth, Figueiredo, Ines, Riisnaes, Ruth, Miranda, Susana, Crespo, Mateus, Flohr, Penny, Mateo, Joaquín, Altavilla, Amelia, Ferraldeschi, Roberta, Bianchini, Diletta, Attard, Gerhardt, Tunariu, Nina, de Bono, Johann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132155/ https://www.ncbi.nlm.nih.gov/pubmed/27246360 http://dx.doi.org/10.1016/j.clgc.2016.04.016 |
Ejemplares similares
-
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015) -
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014) -
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015) -
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
por: Omlin, A, et al.
Publicado: (2013) -
Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
por: Omlin, A, et al.
Publicado: (2014)